Biologics and Cardiovascular Disease

Area of Science:

• Cardiovascular Medicine
• Immunology
• Pharmacology

Background:

• Biologic therapies have become increasingly important for targeted disease treatment.
• Cardiovascular diseases (CVD) share links with inflammatory responses.
• Early data on biologics in CVD originated from rheumatologic patient populations.

Purpose of the Study:

• To review the historical development of biologic therapies for cardiovascular diseases.
• To identify obstacles encountered in the clinical application of biologics for CVD.
• To highlight recent advances and future directions in biologic therapy for CVD.

Main Methods:

• Review of existing literature on biologic therapies and cardiovascular diseases.
• Analysis of data from rheumatologic populations to understand early applications.
• Examination of targeted mechanisms including inflammatory mediators and novel pathways.

Main Results:

• Biologics targeting inflammatory cytokines like tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 have been explored for CVD.
• Interventions targeting non-inflammatory mediators, such as proprotein convertase subtilisin kexin type 9 (PCSK9), are being utilized.
• RNA interference (RNAi) therapy represents an emerging targeted mechanism for cardiovascular intervention.

Conclusions:

• Biologic therapies offer promising targeted approaches for managing cardiovascular diseases.
• Overcoming obstacles in biologic therapy application is crucial for broader CVD treatment.
• Continued research and development in biologics, including RNAi, hold potential for advancing CVD care.